 Connection
Mark Gerich to Tumor Necrosis Factor-alpha
This is a "connection" page, showing publications Mark Gerich has written about Tumor Necrosis Factor-alpha.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.367 |
|
|
|
-
Gerich ME, Pardi DS, Bruining DH, Kammer PP, Becker BD, Tremaine WT. Tacrolimus salvage in anti-tumor necrosis factor antibody treatment-refractory Crohn's disease. Inflamm Bowel Dis. 2013 May; 19(6):1107-11.
Score: 0.301
-
Cohen BL, Fleshner P, Kane SV, Herfarth HH, Palekar N, Farraye FA, Leighton JA, Katz JA, Cohen RD, Gerich ME, Cross RK, Higgins PDR, Tinsley A, Glover S, Siegel CA, Bohl JL, Iskandar H, Ji J, Hu L, Sands BE. Prospective Cohort Study to Investigate the Safety of Preoperative Tumor Necrosis Factor Inhibitor Exposure in Patients With Inflammatory Bowel Disease Undergoing Intra-abdominal Surgery. Gastroenterology. 2022 07; 163(1):204-221.
Score: 0.035
-
Scott FI, Luo M, Shah Y, Lasch K, Vajravelu RK, Mamtani R, Fennimore B, Gerich ME, Lewis JD. Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis. J Crohns Colitis. 2020 Jun 19; 14(5):575-587.
Score: 0.031
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|